Empower Pharmacy
Empower Pharmacy scored 52/100 on Panya's 11-signal vendor rubric. Each signal is scored 0 to 100, the methodology is public, and our affiliate posture is flat-fee · never pay-to-rank. Below is the full per-signal breakdown.
- COA on every lot503B per-batch testing required; April 2025 FDA warning letter cited gaps in microbial-excursion investigation75
- Cold-chain verified503B sterile production standard; FDA warning letter flagged sterile-drug production deficiencies at two Houston facilities70
- Rx legalityApril 30, 2026 FDA proposal to exclude tirzepatide from 503B bulks list (comment period through June 29; final rule likely Q3 2026) materially closes the primary compounding channel. Rx-required + multi-state licensed otherwise; Lilly tirzepatide lawsuit ongoing in Texas federal court (refiled July 2025)45
- Compound identity75
- Dose accuracyFDA warning letter cited labeling omissions that disqualified some 503B exemptions70
- Endotoxin testing503B requires testing; FDA warning letter cited inadequate investigation of microbial excursions70
- Refund postureprescription-fulfillment model; refund handled via partner clinic55
- Channel clarityRx-only via partner clinic; backend pharmacy for many GLP-1 telehealth platforms · primary supply channel sunsetting under the April 30 proposal, telehealth-platform pivot risk material50
- Support qualitysupport routed through prescribing clinic60
- Price transparencyset by partner clinic; not directly listed on Empower site50
- Longitudinal retentionhigh volume during 2023-2025 GLP-1 shortage; Lilly suit + April 2025 FDA letter + April 30 2026 503B-exclusion proposal stack into a converging overhang. Final rule Q3 2026 likely.45
Brand pharmacy supply stable. Compounded channel sunsetting · April 30, 2026 FDA proposal to exclude tirzepatide from the 503B bulks list (comment closes June 29, final rule likely Q3 2026) closes the mass-compounded path. 503A patient-specific compounding survives only with documented medical necessity. Telehealth platforms (Hims, Ro, Mochi) pivoting toward brand prescriptions or oral alternatives.
Recovered from the 2023 shortage. Diabetes-coded insurance straightforward.
Oral semaglutide. Niche fit for needle-averse patients. Lower bioavailability than injectable.
Recovered from the 2023-24 shortage. Insurance coverage expanding under 2025-26 employer plans. Oral Wegovy 25mg launched Jan 2026 at $149/mo · adds a needle-free path. Compounded semaglutide channel similarly narrowing under post-Feb-2025 enforcement-discretion rules.
Lilly-direct LillyDirect channel (US-only) supplements pharmacy distribution. Stable. Brand-channel demand expected to lift through 2026 as compounded pathway closes under the April 30 FDA 503B-exclusion proposal · LillyDirect's at-launch pricing materially undercuts compounded for patients without insurance coverage.
The 11-signal rubric is public.
Identity, dose accuracy, COA, cold-chain, Rx legality, compound identity, endotoxin testing, refund posture, channel clarity, support quality, price transparency, longitudinal retention. Each scored 0 to 100. Vendors that fail our floor are silently filtered out · they don't appear in our match flow at all.
If Empower Pharmacy wants to dispute or update this score, contact partner@panya.health. Score updates are recorded on this page with a public changelog.
Want a match for your situation?
Take the 2-minute quiz. We'll match you against this and the other vendors in your region · based on your dose, urgency, and budget.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.